Delivery Order SPE2DB20D3103-SPE2DB25FP8U3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $3,289.88 under firm fixed pricing. This contract is a child award issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award is non-set-aside and was competitively awarded, with the place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $12,152.93 under a firm fixed-price contract. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement designated SPE2DX and extending through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Jardiance 25 mg tablets (90-count) with a ceiling value of $1,571.08. This contract represents a firm fixed-price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion and extending through December 2026. The award was made through open competition with no set-aside designation. Performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jardiance 10 mg tablets (90-count units) with a ceiling value of $9,798.71. This competitive, non-set-aside award is structured as a firm fixed price delivery order with an ultimate completion date of August 11, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a contract value of $9,749.76. This firm fixed price delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million through December 2026. The award was competitively procured with no set-aside designation, and the place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Jardiance 10 mg tablets (90-count) under a firm fixed-price contract valued at $21,295.85. This non-competitive, competitively awarded delivery order is scheduled for completion by August 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 29, 2025, for the supply of Jardiance 10 mg tablets in a 90-count package. This firm fixed-price delivery order, valued at $11,375.53, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The award was competitively awarded with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $6,155.89. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's significantly larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $1,135.93. This firm fixed-price delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX valued at $999,999,999.00 through December 2026), does not utilize a set-aside designation and represents a competitively awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Jardiance 25 mg tablets in a quantity of 90s, with a ceiling value of $50,074.67. This firm fixed-price delivery order, which is set to complete by September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8U3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Jardiance 25 mg tablets (90-count units) valued at $12,698.24 under a firm fixed price contract. This award represents a child delivery order executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The delivery order is not subject to any set-aside provisions and was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive portfolio includes brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This specific award for Jardiance, a diabetes medication, exemplifies the company's role in supplying pharmaceutical products through the DLA's global pharmaceutical support initiative, which continues to evaluate additional regional prime vendor arrangements to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 8/14/25 |